Myelodysplastic syndrome surgery: Difference between revisions

	Myelodysplastic syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Myelodysplastic syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myelodysplastic syndrome surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myelodysplastic syndrome surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myelodysplastic syndrome surgery
CDC on Myelodysplastic syndrome surgery
Myelodysplastic syndrome surgery in the news
Blogs on Myelodysplastic syndrome surgery
Directions to Hospitals Treating Myelodysplastic syndrome
Risk calculators and risk factors for Myelodysplastic syndrome surgery

Revision as of 21:30, 15 December 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

A stem cell transplant may be a treatment option for younger people and those with high-risk MDS.^[1]

@@ Line 5: / Line 5: @@
 ==Surgery==
 ===Stem cell transplantation===
-[[Stem cell transplantation]], particularly in younger patients (ie less than 40 years of age), more severely affected patients, offers the potential for curative therapy.   Success of bone marrow transplantation has been found to correlate with severity of MDS as determined by the IPSS score, with patients having a more favorable IPSS score tending to have a more favorable outcome with transplantation.<ref>{{cite journal |author=Oosterveld M, Wittebol S, Lemmens W, Kiemeney B, Catik A, Muus P, Schattenberg A, de Witte T |title=The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups |journal=Br J Haematol |volume=123 |issue=1 |pages=81-9 |year=2003 |pmid=14510946}}</ref>
+A stem cell transplant may be a treatment option for younger people and those with high-risk MDS.<ref name=cancerca>Treatment of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.ca/en/cancer-information/cancer-type/leukemia/leukemia/myelodysplastic-syndromes/?region=on. Accessed on December 15, 2015</ref>
 ==References==
 {{reflist|2}}